How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/infection-due-to-enterobacteriaceae.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-11 · How we verify

Infection due to Enterobacteriaceae — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Infection due to Enterobacteriaceae (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Infection due to Enterobacteriaceae, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Avelox	moxifloxacin	Bayer AG	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Azactam	AZTREONAM	Bristol-Myers Squibb	Monobactam Antibacterial [EPC]		1986-01-01
Unasyn	SULBACTAM	Pfizer	beta Lactamase Inhibitor	Serine beta-lactamase-like protein LACTB, mitochondrial	1986-01-01
Fortaz	CEFTAZIDIME	Pai Holdings Pharm	ceftazidime		1985-01-01
Rocephin	ceftriaxone	Generic (originally Roche)	Cephalosporin antibiotic (third-generation)	Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A	1984-12-21
Zinacef	CEFUROXIME	GSK	Cephalosporin Antibacterial	Carbonic anhydrase 2	1983-01-01
Arikayce Kit	AMIKACIN	Bristol-Myers Squibb	Aminoglycoside Antibacterial		1981-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 8 drugs in Infection due to Enterobacteriaceae
Bristol-Myers Squibb · 3 drugs in Infection due to Enterobacteriaceae
Merck & Co. · 2 drugs in Infection due to Enterobacteriaceae
Bayer AG · 2 drugs in Infection due to Enterobacteriaceae
Pai Holdings Pharm · 2 drugs in Infection due to Enterobacteriaceae
Pfizer · 2 drugs in Infection due to Enterobacteriaceae
Generic (originally Roche) · 1 drug in Infection due to Enterobacteriaceae
Assistance Publique - Hôpitaux de Paris · 1 drug in Infection due to Enterobacteriaceae
Novartis · 1 drug in Infection due to Enterobacteriaceae
Novartis Pharmaceuticals · 1 drug in Infection due to Enterobacteriaceae
Tel-Aviv Sourasky Medical Center · 1 drug in Infection due to Enterobacteriaceae
University Hospital, Lille · 1 drug in Infection due to Enterobacteriaceae

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Infection due to Enterobacteriaceae:

Cite this brief

Drug Landscape (2026). Infection due to Enterobacteriaceae — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/infection-due-to-enterobacteriaceae. Accessed 2026-06-11.

Infection due to Enterobacteriaceae full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing